Healthcare Industry News: Applied Pharma Research
News Release - October 28, 2013
APR Applied Pharma Research (APR) announces the European CE approval for Nexodyn(R), a newly developed product for the management of acute and chronic woundsBALERNA, Switzerland--(Healthcare Sales & Marketing Network)--APR announces the grant of the European CE approval of Nexodyn®, a newly developed innovative product intended for use in a variety of wound conditions such as acute wounds, burns and advanced ulcers including venous and pressure ulcers and diabetic foot ulcers. Nexodyn®, characterized by acidic and super-oxidizing features in an easy-to-use formulation, acts by improving the functional conditions of the physiological wound healing process, providing the healthcare professional and the patient with an effective, convenient and patient-friendly treatment option.
The product has been developed based on APR’s proprietary technology TEHCLO®, enabling the production of acidic and super-oxidizing solutions containing free chlorine species, of which stabilized hypochlorous acid in very high concentration (> 95%).
“APR is focused on the innovative development of products covering well-defined unmet medical needs in different therapeutic areas” said Paolo Galfetti, CEO of APR. “With the approval of Nexodyn® APR is enriching its pipeline and expansion in the therapeutic area of the acute and chronic wound management, where the innovative formulation of Nexodyn® contributes to support the normal physiological healing process of advanced wounds to the final benefit of patients’ quality of life. It is APR’s strategic objective to register Nexodyn® in the USA and other target countries.”
About APR Applied Pharma Research s.a.
APR is an independent, international and integrated Healthcare Company headquartered in Switzerland and focused on three major areas: Delivering, Funding and Supporting Innovation in Healthcare. In particular, APR develops and licenses innovative, value added and patented healthcare products and proprietary drug delivery systems primarily in the oral and topical fields; APR also invests in companies or early stage innovative projects and provides a balanced mix of equity funding and/or financing together with APR’s development, scientific, technical, marketing, licensing and management skills and know how; finally, APR supports biotech and pharmaceutical companies in the development of new pharmaceutical projects by providing on a contract basis added value, consultancy and R&D services under contract using a General Contractor approach. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 100 countries worldwide with international sales on a worldwide basis. For press releases and other company information visit: www.apr.ch
Source: Applied Pharma Research
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.